| pubmed-article:16883006 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16883006 | lifeskim:mentions | umls-concept:C1800706 | lld:lifeskim |
| pubmed-article:16883006 | lifeskim:mentions | umls-concept:C0205217 | lld:lifeskim |
| pubmed-article:16883006 | lifeskim:mentions | umls-concept:C0243144 | lld:lifeskim |
| pubmed-article:16883006 | lifeskim:mentions | umls-concept:C0298998 | lld:lifeskim |
| pubmed-article:16883006 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:16883006 | pubmed:dateCreated | 2006-8-2 | lld:pubmed |
| pubmed-article:16883006 | pubmed:abstractText | Idiopathic pulmonary fibrosis (IPF) is characterized by an uncontrolled accumulation and activation of lung fibroblasts. A modulation of fibroblast activation has been observed in various systems with octreotide, a synthetic somatostatin analog with strong affinity for the somatostatin receptor subtype 2 (sst2). One aim of our study was to evaluate the expression of somatostatin receptors in the lungs of patients with IPF. A second aim was to evaluate the relationship between 111In-octreotide uptake and the effect of pulmonary fibrosis as assessed by lung function tests and parameters and by radiologic findings. | lld:pubmed |
| pubmed-article:16883006 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16883006 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16883006 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16883006 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16883006 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16883006 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16883006 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16883006 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16883006 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:16883006 | pubmed:issn | 0161-5505 | lld:pubmed |
| pubmed-article:16883006 | pubmed:author | pubmed-author:CrestaniBruno... | lld:pubmed |
| pubmed-article:16883006 | pubmed:author | pubmed-author:ReubiJean-Cla... | lld:pubmed |
| pubmed-article:16883006 | pubmed:author | pubmed-author:Gruaz-GuyonAn... | lld:pubmed |
| pubmed-article:16883006 | pubmed:author | pubmed-author:Le... | lld:pubmed |
| pubmed-article:16883006 | pubmed:author | pubmed-author:LebtahiRachid... | lld:pubmed |
| pubmed-article:16883006 | pubmed:author | pubmed-author:RaguinOlivier... | lld:pubmed |
| pubmed-article:16883006 | pubmed:author | pubmed-author:SolerPaulP | lld:pubmed |
| pubmed-article:16883006 | pubmed:author | pubmed-author:MarchalJoëlle... | lld:pubmed |
| pubmed-article:16883006 | pubmed:author | pubmed-author:Marchand-Adam... | lld:pubmed |
| pubmed-article:16883006 | pubmed:author | pubmed-author:BraunerMichel... | lld:pubmed |
| pubmed-article:16883006 | pubmed:author | pubmed-author:MoreauSeverin... | lld:pubmed |
| pubmed-article:16883006 | pubmed:author | pubmed-author:DebrayMarie-P... | lld:pubmed |
| pubmed-article:16883006 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16883006 | pubmed:volume | 47 | lld:pubmed |
| pubmed-article:16883006 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16883006 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16883006 | pubmed:pagination | 1281-7 | lld:pubmed |
| pubmed-article:16883006 | pubmed:meshHeading | pubmed-meshheading:16883006... | lld:pubmed |
| pubmed-article:16883006 | pubmed:meshHeading | pubmed-meshheading:16883006... | lld:pubmed |
| pubmed-article:16883006 | pubmed:meshHeading | pubmed-meshheading:16883006... | lld:pubmed |
| pubmed-article:16883006 | pubmed:meshHeading | pubmed-meshheading:16883006... | lld:pubmed |
| pubmed-article:16883006 | pubmed:meshHeading | pubmed-meshheading:16883006... | lld:pubmed |
| pubmed-article:16883006 | pubmed:meshHeading | pubmed-meshheading:16883006... | lld:pubmed |
| pubmed-article:16883006 | pubmed:meshHeading | pubmed-meshheading:16883006... | lld:pubmed |
| pubmed-article:16883006 | pubmed:meshHeading | pubmed-meshheading:16883006... | lld:pubmed |
| pubmed-article:16883006 | pubmed:meshHeading | pubmed-meshheading:16883006... | lld:pubmed |
| pubmed-article:16883006 | pubmed:meshHeading | pubmed-meshheading:16883006... | lld:pubmed |
| pubmed-article:16883006 | pubmed:meshHeading | pubmed-meshheading:16883006... | lld:pubmed |
| pubmed-article:16883006 | pubmed:meshHeading | pubmed-meshheading:16883006... | lld:pubmed |
| pubmed-article:16883006 | pubmed:meshHeading | pubmed-meshheading:16883006... | lld:pubmed |
| pubmed-article:16883006 | pubmed:meshHeading | pubmed-meshheading:16883006... | lld:pubmed |
| pubmed-article:16883006 | pubmed:meshHeading | pubmed-meshheading:16883006... | lld:pubmed |
| pubmed-article:16883006 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16883006 | pubmed:articleTitle | Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. | lld:pubmed |
| pubmed-article:16883006 | pubmed:affiliation | Department of Nuclear Medicine, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France. rachida.lebtahi@bch.aphp.fr | lld:pubmed |
| pubmed-article:16883006 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16883006 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16883006 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16883006 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16883006 | lld:pubmed |
